Nottingham-based biomaterial startup 4D Medicine has raised £3.4 million in Series A funding. The funding round was led by Oshen Holdings and supported by DSW Ventures, SFC Capital, Boundary Capital, and private investors
Founded as a spinout from the universities of Birmingham and Warwick, 4D Medicine has developed 4Degra, a novel resorbable biomaterial used for 3D printing medical implants. The material can be printed to exact shapes required for various medical applications, including tumour removal in breast cancer patients and recovery from surgeries or trauma.
As natural tissue grows through the structure, it gradually erodes and is expelled harmlessly by the body.
Smith, the company’s CEO, said: “Our success in continuing to raise investment despite the difficult market conditions over the last few years is a testament to the belief in the company’s commercial potential and our world-class team.”
Doug Quinn, partner at DSW Ventures, added: “4D’s novel biomaterial platform opens up new possibilities for implants and devices. The company has already attracted attention from large industry players including a potential acquirer. This funding will enable it to apply for regulatory clearance in the US and target opportunities in the £5bn market for resorbable medical devices.”